Efficacy and gastrointestinal tolerability of semaglutide versus sitagliptin in patients with type 2 diabetes: A randomized, controlled trial
Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature
GLP-1 is specifically designed for individuals with a BMI greater than 30 or a BMI greater than 27 with at least one cardiometabolic risk factor, such as high blood pressure, high cholesterol, pre-diabetes, or type 2 diabetes
San Diego County issued its fifth advisory update on the shortage in February, and New York City's health department issued its own advisory in April
Educational reference only This page is a research-context summary, not personal medical advice
Zepbound labeling also directs clinicians to consider treatment response and tolerability when choosing a maintenance dose